Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: Results of a randomized, placebo-controlled trial

Journal of Infectious Diseases

Volumn 198, Issue 12, 2008, Pages 1870-1879

  Tweyongyere, Robert ^a,b   Mawa, Patrice A ^a   Ngom wegi, Sophy ^a   Ndibazza, Juliet ^a   Duong, Trinh ^c   Vennervald, Birgitte J ^e   Dunne, David W ^d   Katunguka Rwakishaya, Eli ^b   Elliott, Alison M ^a,c  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b MAKERERE UNIVERSITY   (Uganda)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e DANISH BILHARZIASIS LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PARASITE ANTIGEN; PLACEBO; PRAZIQUANTEL;

ADULT; ARTICLE; BLOOD CULTURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; PARASITE IDENTIFICATION; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SINGLE DRUG DOSE; TH2 CELL;

ADOLESCENT; ADULT; ANTIGENS, HELMINTH; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PRAZIQUANTEL; PREGNANCY; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES;

EID: 56749131112     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/593215     Document Type: Article

References (48)

1. Frenzel K, Grigull L, Odongo-Aginya E, et al. Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda. Am J Trop Med Hyg 1999; 60:927-31.
2. Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop 2002; 82:139-46.
3. World Health Organization (WHO). Report of the WHO informal consultation on monitoring drug efficacy in the control of schistosomiasis and intestinal nematodes; 8-10 July 1998. Geneva, Switzerland: WHO, 1999.
4. Allen HE, Crompton DW, de Silva N, LoVerde PT, Olds GR. New policies for using anthelmintics in high risk groups. Trends Parasitol 2002; 18:381-2.
5. World Health Organization (WHO). Report of theWHOinformal consultation on the use of praziquantel during pregnancy/lactation and albendazole/ mebendazole in children under 24 months; 8-9 April 2002. Geneva, Switzerland: WHO, 2003:49.
6. World Health Organization (WHO). Report of the scientific working group meeting on schistosomiasis; 14-16 November 2005. Geneva, Switzerland: WHO-TDR, 2006:114.
7. Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 1987; 139:215-20.
8. Brindley PJ, Strand M, Norden AP, Sher A. Role of host antibody in the chemotherapeutic action of praziquantel against Schistosoma mansoni: identification of target antigens. Mol Biochem Parasitol 1989; 34:99-108.
9. Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exp Parasitol 1990; 71:245-8.
10. Modha J, Lambertucci JR, Doenhoff MJ, McLaren DJ. Immune dependence of schistosomicidal chemotherapy: an ultrastructural study of Schistosoma mansoni adult worms exposed to praziquantel and immune serum in vivo. Parasite Immunol 1990; 12:321-34.
11. Fallon PG, Cooper RO, Probert AJ, Doenhoff MJ. Immune-dependent chemotherapy of schistosomiasis. Parasitology 1992; 105(Suppl):S41-8.
12. Nyazema NZ, Mutamiri FF, Mudiwa I, Chimuka A, Ndamba J. Immunopharmacological aspects of praziquantel. Cent Afr J Med 1995; 41:284-8.
13. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933-44.
14. Mutapi F. Heterogeneities in anti-schistosome humoral responses following chemotherapy. Trends Parasitol 2001; 17:518-24.
15. Joseph S, Jones FM, Walter K, et al. Increases in human T helper 2 cytokine responses to Schistosoma mansoni worm and worm-tegument antigens are induced by treatment with praziquantel. J Infect Dis 2004; 190:835-42.
16. Roberts M, Butterworth AE, Kimani G, et al. Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection. Infect Immun 1993; 61:4984-93.
17. Medhat A, Shehata M, Bucci K, et al. Increased interleukin-4 and interleukin-5 production in response to Schistosoma haematobium adult worm antigens correlates with lack of reinfection after treatment. J Infect Dis 1998; 178:512-9.
18. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol 2002; 2:499-511.
19. Remoue F, Rogerie F, Gallissot MC, et al. Sex-dependent neutralizing humoral response to Schistosoma mansoni 28GST antigen in infected human populations. J Infect Dis 2000; 181:1855-9.
20. Gehrz RC, Christianson WR, Linner KM, Conroy MM, McCue SA, Balfour HH Jr. A longitudinal analysis of lymphocyte proliferative responses to mitogens and antigens during human pregnancy. Am J Obstet Gynecol 1981; 140:665-70.
21. Lederman MM. Cell-mediated immunity and pregnancy. Chest 1984; 86:6S-9S.
22. Chaouat G, Ledee-Bataille N, Dubanchet S. Immune cells in uteroplacental tissues throughout pregnancy: a brief review. Reprod Biomed Online 2007; 14:256-66.
23. Formby B. Immunologic response in pregnancy: its role in endocrine disorders of pregnancy and influence on the course of maternal autoimmune diseases. Endocrinol Metab Clin North Am 1995; 24:187-205.
24. Novato-Silva E, Gazzinelli G, Colley DG. Immune responses during human schistosomiasis mansoni. XVIII. Immunologic status of pregnant women and their neonates. Scand J Immunol 1992; 35:429-37.
25. Elliott AM, Kizza M, Quigley MA, et al. The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebocontrolled, factorial trial of deworming interventions delivered in pregnancy and early childhood [ISRCTN32849447]. Clin Trials 2007; 4:42-57.
26. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972; 14:397-400.
27. Webster M, Fulford AJ, Braun G, et al. Human immunoglobulin E responses to a recombinant 22.6-kilodalton antigen from Schistosoma mansoni adult worms are associated with low intensities of reinfection after treatment. Infect Immun 1996; 64:4042-6.
28. Elliott AM, Hurst TJ, Balyeku MN, et al. The immune response to Mycobacterium tuberculosis in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assay in an epidemiological study. Int J Tuberc Lung Dis 1999; 3:239-47.
29. Weir RE, Morgan AR, Britton WJ, Butlin CR, Dockrell HM. Development of a whole blood assay to measure T cell responses to leprosy: a new tool for immuno-epidemiological field studies of leprosy immunity. J Immunol Methods 1994; 176:93-101.
30. Robertson SA. Control of the immunological environment of the uterus. Rev Reprod 2000; 5:164-74.
31. Mellor AL, Munn DH. Extinguishing maternal immune responses during pregnancy: implications for immunosuppression. Semin Immunol 2001; 13:213-8.
32. Guleria I, Sayegh MH. Maternal acceptance of the fetus: true human tolerance. J Immunol 2007; 178:3345-51.
33. Wilder RL. Hormones, pregnancy, and autoimmune diseases. Ann N Y Acad Sci 1998; 840:45-50.
34. Al-Shammri S, Rawoot P, Azizieh F, et al. Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis. J Neurol Sci 2004; 222:21-7.
35. Doria A, Iaccarino L, Arienti S, et al. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol 2006; 22:234-41.
36. Dunne DW, Vennervald BJ, Booth M, et al. Applied and basic research on the epidemiology, morbidity, and immunology of schistosomiasis in fishing communities on Lake Albert, Uganda. Trans R Soc Trop Med Hyg 2006; 100:216-23.
37. de Jesus AR, Silva A, Santana LB, et al. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis 2002; 185:98-105.
38. Hoffmann KF, Wynn TA, Dunne DW. Cytokine-mediated host responses during schistosome infections; walking the fine line between immunological control and immunopathology. Adv Parasitol 2002; 52:265-307.
39. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol Rev 2004; 201:156-67.
40. Booth M, Mwatha JK, Joseph S, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol 2004; 172:1295-303.
41. Mwatha JK, Kimani G, Kamau T, et al. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J Immunol 1998; 160:1992-9.
42. Oliveira LFA, Moreno EC, Gazzinelli G, et al. Cytokine production associated with periportal fibrosis during chronic schistosomiasis mansoni in humans. Infect Immun 2006; 74:1215-21.
43. Fitzsimmons CM, Joseph S, Jones FM, et al. Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E. Infect Immun 2004; 72:4023-30.
44. Hatz CF, Vennervald BJ, Nkulila T, et al. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg 1998; 59:775-81.
45. Vennervald BJ, Booth M, Butterworth AE, et al. Regression of hepatosplenomegaly in Kenyan school-aged children after praziquantel treatment and three years of greatly reduced exposure to Schistosoma mansoni. Trans R Soc Trop Med Hyg 2005; 99:150-60.
46. Dunne DW, Butterworth AE, Fulford AJ, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992; 22:1483-94.
47. Dunne DW, Pearce EJ. Immunology of hepatosplenic schistosomiasis mansoni: a human perspective. Microbes Infect 1999; 1:553-60.
48. Mutapi F, Ndhlovu PD, Hagan P, et al. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis 1998; 178:289-93.